Based on @ events , median progression-free survival was @ months ( @ % CI @-@ ) in the dabrafenib and trametinib group and @ months ( @-@ ) in the dabrafenib only group ( HR @ , @ % CI @-@ ; p = @ ; unadjusted for multiple testing ) .